Background: Despite advancement in medical and interventional treatments, cardiac remodeling may occur in almost 60% of patients who suffered a myocardial infarction. Stem cell therapy is specifically addressed to myocardial hypoperfusion and loss of myocardial mass, with the major goal in prevention and improvement of cardiac remodeling. Objectives: We aimed to investigate the feasibility, safety and effectiveness of autologous bone marrow stem cell therapy in patients with acute myocardial infarction having moderate to severe systolic dysfunction 6 months after transplantation. Methods: Eighteen patients with a first acute myocardial infarction with ST-segment elevation (STEMI) were included in the study; they were assigned either to intracoronary infusion of bone marrow cell suspension or to the control group. Results: At 6 months follow-up, there were no significant differences between groups regarding major adverse cardiac events. Furthermore, cell therapy led to smaller left ventricular volumes and significantly improved function. Conclusions: The autologous bone marrow stem cell therapy has proven to be a reliable method that can be used in clinical practice in well selected cases. The precise indications, the optimal timing for cell administration and the processing method are still to be determined, as well as the long term effects of cellular therapy.
INTRODUCTION INTRODUCTION
infarction (MI), in spite of medical, surgical or interventional treatment (1) (2) (3) . As shown by studies conducted so far, cardiac remodeling is a complex process, affecting the entire myocardium on structural, cellular and molecular levels. Various types of treatment (whether pharmacological, interventional or surgical) aim to prevent, slow down or even reverse cardiac remodeling.
A progress in this sense is represented by stem cell (SC) therapy which targets myocardial hypoperfusion and viable tissue loss; this cutting-edge therapy is used "on top of" recommended treatment guidelines.
Objectives
The main objective was to evaluate the feasibility and safety of autologous bone marrow stem cell (ABMSC) therapy in STEMI patients with moderate to severe systolic dysfunction.
The secondary objectives were to assess the effect of ABMSC on left ventricular systolic function and left ventricular remodeling respectively, 6 months after transplantation.
METHODS METHODS

Patient selection
This prospective pilot -study was conducted on a total of 18 patients with acute myocardial infarction with ST-segment elevation (STEMI) and angioplasty with stent implantation, admitted to Cardiology Department of Clinical Emergency Hospital of Bucharest. Eligibility criteria were as follows: age between 18 and 81, first STEMI presenting within 12 hours of symptoms onset, myocardial revascularization by angioplasty and left ventricular ejection fraction (LVEF) ≤ 40%.
The main exclusion criteria were -as previously detailed: pregnancy or lactation, hemodynamic instability, NYHA class IV, severe valvular disease, intraventricular thrombosis, malignant tumors, renal, hepatic or respiratory severe impairment, active infections, alcohol or drug dependence, any other severe comorbidity meant to alter patient prognosis, as well as the refuse to participate to the study (4) .
The ethics review board of Clinical Emergency Hospital of Bucharest approved the protocol, and the study was conducted in accordance with the Declaration of Helsinki. All subjects gave signed informed consent.
Study design
Patients were divided into two groups: the experimental group receiving autologous bone marrow stem cell (ABMSC) transplantation (7 patients) and the control group in which were included those who refused cell transplantation (11 patients).
Complete clinical examinations and biochemical analysis of blood samples were performed at baseline and 6 months after MI, as well as echocardiography (2D and 3D respectively) and coronary angiography. In addition, at 6 months follow-up, 24h ECG monitoring was completed ( figure 1) .
Patients in both groups received standard therapy according current guidelines and were assessed using the same methods. Neither bone marrow aspiration nor sham injection was performed in the control group.
Cell preparation and administration:
Seven to thirteen days after MI 50 ml of bone marrow were aspirated into heparin-treated syringes from the iliac crest under local anaesthesia. The bone marrow aspirate was stored at room temperature together with 10 ml of venous blood used to produce patients' own serum. Progenitor cells were isolated and enriched within the mononuclear cell population by Ficoll centrifugation, as previously described (4) whole procedure was carried out in Cell Culture Laboratory equipped according to international standards to fulfil all conditions required by a "clean room". The assessment of the absolute number of CD34+CD45dim progenitor cells in the blood marrowbefore and after centrifugation -was performed as formerly depicted (5) . The administration of cells was done by intracoronary injection, according to the stopflow technique described by Strauer and collegues (6) .
Statistical analysis
Data were expressed as percentages for categorical variables and as mean ± standard deviation for numeric variables. Continuous variables were tested for normal distribution by Kolmogorov-Smirnov test using Lilliefors' correlation. To compare groups we used Student test for quantitative variables with normal distribution, respectively chi-square test for nominal or ordinal variables. All tests were two-sided. Statistical analysis was performed using SPSS software version 17.0 or Microsoft Excel for Windows 7.0. Data with p <0.05 were considered statistically significant.
RESULTS RESULTS
A total of 18 patients were included into the study. The patients' initial data are illustrated in As regard to major adverse cardiac events (MACE), there were no significant differences between groups, but with lower incidence for severe ventricular arrhythmias, readmission for heart failure and coronary revascularization in SC treated group ( plant there were no significant changes in LV volumes between groups, but there was a significant improvement (p=0.043) regarding 2D LVEF ( figure 2) .
In addition, in ABMSC group LVEF enhancement was significant (8.65% for 2D LVEF, 7.83% for 3D LVEF) as opposed to control group where the improvement was minor (1.65% for 2D LVEF, 2.7% for 3D LVEF) as summarized in figure 3 .
During the 6 months no adverse effects were observed following administration of stem cell therapy.
DISCUSSION DISCUSSION
Bone marrow derived haematopoietic stem cells have been demonstrated to exhibit differentiation capacity towards myocardial linages in vitro, and thus being particularly interesting for the treatment of cardiac pathologies. Clinical trials conducted so far utilizing bone marrow derived hematopoietic stem cells were able to prove the safety and feasibility of this cell population for cardiac applications (7). The ground-breaking work of Orlic and collaborators showing improved cardiac function as result of cells administration in a mouse model of myocardial ischaemia, is the rationale of bone marrow stem cells use in ischemic cardiac disease (8, 9) . This theory was proved particularly attractive, and, therefore, over 33 randomized clinical trials involving a total of 1765 participants (10) were carried out in acute settings.
The main objective of our study was to assess the feasibility and safety of cellular therapy after 6 months in STEMI patients with moderate-to severe systolic dysfunction.
Considering the occurrence of MACE, in the case of our study there were no significant differences between groups -probably due to the small number of patients included and the relatively short follow-up period. However, the incidence of severe ventricular arrhythmias, readmission for heart failure and coronary revascularization was inferior in the SC treated group than in control group (table 3) .
This data are in agreement with literature reports, patients with marrow-derived SC transplant exhibiting a trend toward a lower rate of adverse events (6), (11) (12) (13) (14) , or even a significant decrease when cells were administered during days four-seven (15) .
One of the possible mechanisms by which cell therapy could reduce restenosis process and/or atherosclerosis progression might be reendothelization stimulation and vascular regeneration. Moreover, marrow cells could contribute to a better recovery of coronary flow reserve, thus explaining the decrease in future recurrence of acute coronary events (11) .
Yet, there were some cases of reinfarction or accelerated atherosclerosis secondary to bone marrow stem cells intracoronary delivery: 7 patients out of 19 had stent stenosis 4 months after CD133+ cells therapy (16) . As the authors stated, there are several possible mechanisms for this "Janus-like" effect (17) .
The total number of CD133+ cells injected was higher than in other studies, patients with elevated number of transplanted CD133+ cells being more affected by distal luminal loss. Another explanation refers to an imbalance between pro-atherogenic and antiatherogenic factors, taking into account that these patients displayed lower levels of interleukin-10 and higher levels of serum VEGF-A. The last, but not the least, in-stent proliferation might be related to repetitive balloon occlusion at the time of the cell injection, albeit at low inflation pressure, by impairing ongoing reendothelialization.
Accelerated atherosclerosis succeeding intracoronary injection of bone marrow cells was confirmed by some researchers (18) , but was refuted by recent studies (14, 19) .
As regard to SC therapy antiremodeling effect, literature data reported heterogeneous results, even when comparing recent large meta-analysis. Accordingly, either there was no clear effect on LVEDV, but with a significant reduction in LVESV (10, 20, 21) , either cell therapy significantly reduced both LV volumes (22, 23) .
In our study, although LV volumes absolute changes didn't reach statistical significance, we observed a lower increase of LVEDV and a mild reduction of LVESV in ABMSC group compared with control group.
This outcome on LV volumes was reflected also on LVEF which improved significantly in the experimental group, while in control group the same variable showed a lesser recovery (8.64 ± 3.14% vs. 1.61 ± 7.56%, P < 0.05) ( figure 2) .
LVEF is the most common parameter use to evaluate the effect of cellular therapy in acute myocardial infarction, with most studies reporting a mild improvement of systolic function (2.9-9.3%) in SC treated patient compared to control group (10, (20) (21) (22) 24) .
Our data are generally consistent with those reported in the literature. It is worth mentioning that while most of the studies conducted so far included patients with minor to moderate LV systolic dysfunction (10, 22) , our research focused on patients with severe impaired LV function.
The main limitation of our research is represented by the small number of patients enrolled, this primarily being due to strict inclusion criteria, (i.e. LVEF < 40%), but also to patients and families reluctance to accept a novel -yet least broadcasted on a national scaletherapeutic method. Consequently, the study lacked the necessary power to detect statistically significant differences in terms of major adverse effects. Still, this pilot trial could offer required foundation for upcoming larger studies.
CONCLUSIONS CONCLUSIONS
Our study -although comprising a small number of patients -attested the feasibility and safety of this pioneering therapy in patients suffering a large STEMI and consequent depressed cardiac function. The precise indications, the optimal timing for cell administration and the processing method are still to be determined, as well as the long term effects of cellular therapy.
